PCSA - Processa Pharmaceuticals, Inc.
IEX Last Trade
0.909
0 0%
Share volume: 0
Last Updated: Fri 27 Dec 2024 06:57:28 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$0.91
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
14.31%
1 Month
-2.36%
3 Months
-30.15%
6 Months
-54.21%
1 Year
-88.34%
2 Year
-18.21%
Key data
Stock price
$0.91
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.40 - $7.40
52 WEEK CHANGE
-$85.70
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
Company detail
CEO: David Young
Region: US
Website: processapharmaceuticals.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: processapharmaceuticals.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Processa Pharmaceuticals, Inc. focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the. treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company was incorporated in 2011 and is based in Hanover, Maryland.
Recent news